The EPS beat and extended cash runway are mildly positive, but the company remains pre-revenue and the stock has a history of poor post-earnings performance. Watch for the CNTY-813 IND filing in Q4 2026 as a key catalyst. Consider that the $135M placement in January may overhang near-term price action.
Price Chart
Executive Summary
Century Therapeutics reported Q1 2026 EPS of -$0.11, beating the -$0.17 consensus by 35%, with zero revenue (in line). The company highlighted cash of $217M, sufficient into Q1 2029, and progress on CNTY-813 (IND expected Q4 2026). The net loss widened to $21.6M from a prior-year $76.6M net income due to the absence of collaboration revenue.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.11 vs consensus -$0.17 (beat of 35%)
- Revenue $0 (consensus $0) vs $109M in Q1 2025
- Cash, equivalents, and investments $217M as of March 31, 2026
- Net cash used in operations $25.3M vs $34.6M YoY
- CNTY-813 IND submission on track for Q4 2026; initial clinical data expected 2H 2027
- CNTY-308 IND-enabling activities continuing; clinical trial planned in 2026
- Completed $135M private placement in January 2026
Financial Impact
EPS beat of ~35% vs consensus; cash position increased by $100M sequentially
Risk Factors
- Pre-revenue, no product sales expected until at least 2027
- Clinical trial risks for CNTY-813 and CNTY-308
- Potential dilution from January 2026 PIPE and future capital needs
- Historical earnings call subsequent stock moves have been negative on average
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293915 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.45 (−5.23%) |
Oct 2, 2026 25d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.45 (−5.23%) |
Sep 22, 2026 5w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.45 (−23.28%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.45 (−25.26%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.45 (−26.02%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.45 (+26.02%) |
Jun 16, 2026 19w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.45 (−35.56%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.45 (−33.49%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.45 (−31.60%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.45 (−31.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers